Opthea Limited (ASX: OPT) - Share Price
Current share price for OPT : $0.016 0.001 (6.67%)+
Opthea Limited (OPT), an ASX-listed company, is an ASX listed biopharmaceutical company which researches and develops novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. Since FY2014, the Company has been committed to the development of new therapies for the treatment of serious eye diseases that affect the back of the eye, or retina, and lead to vision loss. The Company's lead candidate was sozinibercept a VEGF C/D trap inhibitor being developed for use in conjunction with VEGF A inhibitors for the treatment of wet AMD and other retinal diseases.
OPT General Information +
| ASX Code | OPT |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 21 |
| OPT Share Price | $0.016 |
| Day High | $0.016 |
| Day Low | $0.014 |
| Last Close | $0.015 |
| OPT Share Price Movement | $0.00 ( 6.67% ) |
Prices as at 16:40, 16 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Opthea Limited (OPT) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Opthea Limited (OPT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Opthea Limited (OPT) price-sensitive announcements
OPT - Reinstatement to Official Quotation
Opthea Limited announced the reinstatement of its trading on the ASX following the complet
Opthea Limited (OPT)
3 Jun 2026 | 8:48 AM
3 Jun 2026 | 8:48 AM
OPT - Reinstatement to ASX and Update on LAM Development Program
Opthea Limited, an Australian biotechnology company, announced its reinstatement to the Au
Opthea Limited (OPT)
3 Jun 2026 | 8:48 AM
3 Jun 2026 | 8:48 AM
OPT - Quarterly Activities/Appendix 4C Cash Flow Report
The document is a Quarterly Activities and Appendix 4C Cash Flow Report from Opthea Limite
Opthea Limited (OPT)
30 Apr 2026 | 9:08 AM
30 Apr 2026 | 9:08 AM
OPT - Long Term Suspended Entities
The document lists Opthea Limited (OPT) amongst entities subject to long-term suspension f
Opthea Limited (OPT)
17 Apr 2026 | 2:52 PM
17 Apr 2026 | 2:52 PM
Opthea Limited (OPT) Recent ASX Announcements
OPT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$248.46 | -$20.30 | -61.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$332.49 | -$52.10 | 23.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$214.96 | -$42.20 | 26.70% | 0.00 | 0.00 | 0.00% | 0.0% |
OPT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $51,488M | 0.1108 | -0.1355 | 0.0438 | 11.5284 | 13.3357 | 12.7765 | 4.15% | 3.33% | 3.46% |
| Clinuvel Pharmaceuticals Limited (CUV) | $452M | 0.0287 | 0.0233 | 0.0942 | 12.4791 | 12.1955 | 11.1457 | 0.56% | 0.81% | 1.31% |
| Mesoblast Limited (MSB) | $2,524M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Opthea Limited (OPT) | $19M | -0.6106 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,616M | -1.3893 | 0.0000 | -0.1297 | 0.0000 | 255.6391 | 293.7365 | 0.00% | 0.00% | 0.00% |
OPT Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Jeremy Levin | Non-Executive Chairman, Non-Executive Director | 12 Oct 2020 |
| Mr Lawrence Bernard Gozlan | Non-Executive Director | 24 Jul 2020 |
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | 15 Nov 2024 |
Opthea Limited (OPT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Mar 2024 | BALDWIN, Megan | Sell | Indirect Shares | 3,012,277 | $0.550 | $1,656,752.350 |
| 1 Mar 2024 | BALDWIN, Megan | Sell | Direct Shares | 987,723 | $0.550 | $543,247.650 |
| 28 Nov 2022 | BALDWIN, Megan | Buy | Indirect Shares | 355,901 | $0.480 | $170,832.480 |
See all changes in directors' interest & trades for Opthea Limited (OPT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
OPT Management
| Name | Position |
|---|---|
| Judith Robertson | Chief Commercial Officer |
| Tom Reilly | Chief Financial Officer |
| Hamish George | Chief Financial Officer,Joint Company Secretary |
| Parisa Zamir | Chief Medical Officer |
| Megan Baldwin | Founder, Chief Innovation Officer and Executive Director |
| Stephanie Vipond | Joint Company Secretary |
OPT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Opthea Limited (OPT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 319,779,459 (25.97%) | Regal Funds Management Pty Limited |
| 99,442,577 (8.08%) | The Bank of New York Mellon Corporation |
OPT Calendar of Events
| Date | Event |
|---|---|
| 01 March 2027 | Report (Interim) |
| 14 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
